News | July 13, 2022
Eversana partners with Compai Pharma to expand commercialisation services across APAC
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
The combined company will be able to better serve both our global and regional customers with local production
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Subscribe To Our Newsletter & Stay Updated
